Aim: To investigate and compare the prevalence of biological complications and failure of implants placed in pristine vs. augmented sites after a mean observation period of at least 10 years.
| INTRODUCTION
Outcomes from preclinical studies indicated that the alveolar ridge undergoes resorptive processes following tooth extraction impacting on the bony envelope for an ideal prosthetically driven implant placement (Araújo & Lindhe, 2005) .
Findings in posterior extraction sites demonstrated that within 1 year, half of the alveolar ridge width is resorbed, of which 2/3 occurred during the first 3 months (Schropp, Wenzel, Kostopoulos, & Karring, 2003) . Moreover, results from clinical studies showed a substantial amount of vertical bone resorption on the vestibular aspect of the alveolar process (Araújo & Lindhe, 2005; Cardaropoli, Araújo, & Lindhe, 2003; Chappuis et al., 2015) . Interestingly, thickening of the soft tissue following tooth extraction was observed in sites with a facial alveolar bone thickness < 1 mm masking underlying bone deficiencies (Chappuis, Bornstein, Buser, & Belser, 2016) . This fact may severely compromise optimal three-dimensional implant positioning (Atwood, 1971 (Atwood, , 1973 . Therefore, in order to achieve primary implant stability and successful osseointegration, simultaneous or staged lateral and/ or vertical bone augmentation procedures are needed to manage the reconstruction of atrophic alveolar ridges (Milinkovic & Cordaro, 2014; Urban et al., 2016) . Based on recent advances in regenerative technologies, bone augmentation procedures are nowadays performed with minor invasiveness due to the use of bone substitutes and barrier membranes (Kuchler & von Arx, 2014) .
Recently, controversial data on the long-term survival rates of implants placed in augmented vs. pristine bone have been reported (Chappuis, Cavusoglu, Buser, & von Arx, 2017; Daubert, Weinstein, Bordin, Leroux, & Flemmig, 2015; Tran et al., 2016; Urban et al., 2016; Visser, Stellingsma, Raghoebar, Meijer, & Vissink, 2016) . For example, while some studies showed comparable outcomes in terms of implant survival rates and crestal bone loss (Chappuis et al., 2017; Urban et al., 2016) , other studies reported inferior outcomes for implants placed in augmented sites (Daubert et al., 2015; Tran et al., 2016; Visser et al., 2016) .
A recent systematic review with meta-analysis reported subjectbased estimated weighted mean prevalences and ranges for periimplant diseases derived from longitudinal studies (Derks & Tomasi, 2015) . The prevalence for peri-implant mucositis amounted to 43% ranging from 19% to 65% and for peri-implantitis to 22% ranging from 1% to 47%, respectively (Derks & Tomasi, 2015) . Moreover, several cross-sectional studies reported comparable data to those conducted in longitudinal ones (Aguirre-Zorzano, Estefania-Fresco, Telletxea, & Bravo, 2015; Dalago, Schuldt Filho, Rodrigues, Renvert, & Bianchini, 2017; Daubert et al., 2015; Konstantinidis, Kotsakis, Gerdes, & Walter, 2015; Monje, Wang, & Nart, 2017; Rokn et al., 2017; Schwarz et al., 2017) .
Despite the fact that placement of dental implants in conjunction with augmentation procedures is well documented and was shown to yield high predictability in terms of implant survival rates and volume stability (Buser et al., 2013; Elnayef et al., 2017) , comparative knowledge between the long-term prevalence of biological complications at implants placed in pristine vs. augmented sites is lacking.
Hence, the aim of the present systematic review was to investigate and compare the prevalence of biological complications and failure of implants placed in pristine vs. augmented sites after a mean observation period of at least 10 years.
| MATERIAL AND METHODS

| Study registration
The review protocol was registered and allocated the identification number CRD42017049602 in the PROSPERO international prospective register of systematic reviews hosted by the National Institute for Health Research (NIHR), University of York, UK, Center for Reviews and Dissemination.
| Reporting format
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were adopted throughout the process of the present systematic review (Moher, Liberati, Tetzlaff, & Altman, 2009; Moher et al., 2015) .
| Population (P), exposure (E), comparison (C) and outcomes (O) (PECO)
| Population
Edentulous and partially edentulous patients with osseointegrated titanium/titanium alloy dental implants.
| Exposure
Dental implants placed in augmented sites prior or simultaneous to implant placement, including alveolar ridge preservation and/or vertical/lateral ridge augmentation.
| Comparison
Dental implants placed in sites not requiring augmentation procedures prior to or in conjunction with implant placement (i.e. pristine sites).
| Outcome
Primary outcome: Prevalence of biological complications (i.e., periimplant mucositis and peri-implantitis).
Secondary outcome: Prevalence of implant failure (i.e. implant loss).
| Focused questions
The focused questions were adapted using the PECO criteria (Stone, 2002 
| Unpublished literature search
In order to further identify potential articles for inclusion, grey literature was searched in the register of clinical studies hosted by the US National Institutes of Health (www.clinicaltrials.gov) and in the multidisciplinary European database (www.opengrey.eu).
| Study selection
| Inclusion criteria
The following inclusion criteria were applied:
• Clinical studies with all levels of evidence 
| Exclusion criteria
The following exclusion criteria were applied:
• Preclinical studies
• Narrative reviews (Landis & Koch, 1977) . Eligibility assessment was performed firstly through titles and abstract analysis and secondly through full-text analysis. In order to avoid exclusion of potentially relevant articles, abstracts providing unclear results were included in the full-text analysis. If necessary, authors were contacted for clarifications. From all studies of potential relevance, full text was obtained for independent assessment by the two reviewers against the stated inclusion criteria. Any disagreement was resolved by discussion among the three reviewers.
In the event of multiple publications on the same patient sample, relevant data on the primary and secondary outcome measures were extracted from the publication with a mean follow-up ≥ 10 years.
| Data collection
From the selected articles fulfilling the inclusion criteria, data addressing the primary and secondary outcome measures were extracted for analysis.
| Quality assessment
The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized, non-interventional studies was applied (Wells et al., 2011) .
The topics evaluated were selection of study groups, comparability of participants and outcome. Each included study received a maximum of 13 points for cohort studies and of 10 points in case-control studies.
The criteria used to evaluate the quality of the selected random- 
| Data synthesis
Preliminary evaluation of the selected publications revealed considerable heterogeneity between the studies with respect to design and sample characteristics. Consequently, a qualitative report of the data was planned by applying descriptive methods and, if possible, a quantitative data synthesis for meta-analyses was applied.
| Data analysis
The I 2 statistic test was applied to quantify heterogeneity among studies. After grouping data with respect to the use or not of an augmentation procedure, meta-analyses were performed to estimate overall prevalence at patient and at implant levels for the following outcomes: peri-implant mucositis, peri-implantitis and implant failure, using a specific software for meta-analysis 
| RESULTS
| Study selection
A total of 852 records were identified through the electronic search eases around implants placed in pristine sites (Donati et al., 2016; Roccuzzo, Bonino, et al., 2014; Tenenbaum et al., 2017; Zuffetti et al., 2016) (Table 2a) , three in augmented sites (Roccuzzo, Gaudioso, et al., 2014; Roccuzzo et al. 2017; Simion et al., 2016) (Table 2b ) and one in both pristine and augmented sites (Daubert et al., 2015) , respectively (Table 2c ). An interexaminer Cohen's kappa score of 0.93 was calculated.
| Meta-analyses
Data were extracted from the selected papers and grouped according to patient characteristics as reported in the articles (i.e., periodontal conditions, smoking history, adherence to supportive periodontal therapy, loading time). The presence or absence of an augmentation procedure was used as a covariate for the analysis.
| Prevalence of biological complications and implant failure
The number of events on the total number observed for reported biological complications was entered in the meta-analysis software. Six publications provided data for estimating prevalence of peri-implant mucositis at patient level (Roccuzzo, Bonino, et al., 2014; Roccuzzo, Gaudioso, et al., 2014; Roccuzzo et al. 2017; Simion et al., 2016; Tenenbaum et al., 2017; Zuffetti et al., 2016) . In those publications, data were reported according to subgrouping, resulting in seven clusters for patients with pristine and three clusters for patients with augmented sites, respectively.
Seven publications provided data on the prevalence of periimplantitis at patient level (Donati et al., 2016; Roccuzzo, Bonino, et al., 2014; Roccuzzo, Gaudioso, et al., 2014; Roccuzzo et al. 2017; Simion et al., 2016; Tenenbaum et al., 2017; Zuffetti et al., 2016) .
Subgroup analysis resulted in eight clusters for patients with pristine and three clusters for augmented sites, respectively.
Seven publications provided data on mucositis and on periimplantitis at implant level (Daubert et al., 2015; Donati et al., 2016; Roccuzzo, Gaudioso, et al., 2014; Roccuzzo et al. 2017; Simion et al., 2016; Tenenbaum et al., 2017; Zuffetti et al., 2016) , with six clusters for pristine and four clusters for augmented sites, respectively.
Data on implant failure at patient level could be extracted from seven publications (Donati et al., 2016; Roccuzzo, Bonino, et al., 2014; Roccuzzo, Gaudioso, et al., 2014; Roccuzzo et al. 2017; Simion et al., 2016; Tenenbaum et al., 2017; Zuffetti et al., 2016) , with eight groups for pristine sites and three groups for augmented sites, while six publications provided data for failure at implant level (Daubert et al., 2015; Donati et al., 2016; Roccuzzo, Bonino, et al., 2014; Roccuzzo et al. 2017; Tenenbaum et al., 2017; Zuffetti et al., 2016) , with nine groups for pristine and two for augmented sites, respectively.
| Meta-analyses at patient level
| Peri-implant mucositis
The total number of patients observed was 321, 242 for pristine sites and 79 for augmented sites. The meta-analysis of prevalence of periimplant mucositis at patient level yielded weighted mean values of 22.4% (95% CI 6%-38%) for pristine and of 19.6% (95% CI 0%-40%) for augmented sites, respectively. Heterogeneity as expressed by the I 2 test was 93% for pristine and 88% for augmented sites, respectively (Figure 2 ). Studies on implants placed in prisƟne sites included in meta-analysis (n = 4) Table 2a Study on implants placed in prisƟne and augmented sites included in meta-analysis (n = 1) Table 2c Studies on implants placed in augmented sites included in meta-analysis (n = 3) Table 2b ArƟcles excluded based on full-text assessment (n = 34) Table 1 Full-text arƟcles assessed for eligibility (n = 8)
| Peri-implantitis
The total number of patients observed was 351, 272 for pristine sites and 79 for augmented sites. The prevalence of peri-implantitis at patient level was estimated to a weighted mean of 10.3% (95% CI 4%-17%) for pristine sites and of 17.8% (95% CI 0%-37%) for augmented sites. Heterogeneity as expressed by the I 2 test was 80%
for pristine and 87% for augmented sites, respectively (Figure 3 ). 
T A B L E 2 Characteristics of the included studies on implants placed in (a) pristine sites, (b) augmented sites and (c) pristine and augmented sites, respectively [In PDF format, this T A B L E 2 (additional columns)
| Implant failure
The total number of patients observed was 352, 273 for pristine sites and 79 for augmented sites. The prevalence of implant failure at patient level was estimated to a weighted mean of 2.5% (95% CI 1%-4%) for pristine sites and of 3.6% (95% CI 0%-8%) for augmented sites. Heterogeneity as expressed by the I 2 test was 0% in both pristine and augmented sites, respectively (Figure 4 ).
| Meta-analyses at implant level
| Peri-implant mucositis
The total number of implants observed was 642, 415 for pristine sites and 227 for augmented sites. The prevalence of peri-implant mucositis at implant level presented a weighted mean value of 21.2%
(95% CI 4%-38%) for pristine sites and of 24.6% (95% CI 6%-44%)
for augmented sites. Heterogeneity as expressed by the I 2 test was 97% for pristine and 93% for augmented sites, respectively ( Figure 5 ).
| Peri-implantitis
The total number of implants observed was 642, 415 for pristine sites and 227 for augmented sites. The prevalence of peri-implantitis at implant level presented a weighted mean value of 7.5% (95% CI 2%-13%) for pristine sites and of 9.7% (95% CI 4%-15%) for augmented sites. Heterogeneity as expressed by the I 2 test was 84%
for pristine and 56% for augmented sites, respectively ( Figure 6 ).
| Implant failure
The total number of implants observed was 739, 667 for pristine sites and 72 for augmented sites. The prevalence of failure at implant level presented a weighted mean value of 2.4% (95% CI 1%-4%) for pristine sites and of 6.5% (95% CI 0%-15%) for augmented sites.
Heterogeneity as expressed by the I 2 test was 34% for pristine and 60% for augmented sites, respectively (Figure 7) .
Collectively, as indicated in the Forest plots by the overlap of the 95% confidence intervals, no statistically significant differences (p > .05) were observed between implants placed in pristine vs. augmented sites for any outcome variables both at patient and at implant levels, respectively.
| Quality assessment
Five case-series studies (Donati et al., 2016; Roccuzzo, Bonino, et al., 2014; Roccuzzo et al. 2017; Simion et al., 2016; Tenenbaum et al., 2017) , one case-control (Roccuzzo, Gaudioso, et al., 2014) and one cross-sectional study (Daubert et al., 2015) were assessed by means of the NOS (Wells et al., 2011) . The mean ± standard deviation (SD)
NOS score was 4.8 ± 1.8 for "selection" (median: 4, interquartile range 
Crosssectional 10.9 ± 1.5 (8. DBBM, deproteinized bovine bone mineral; DFDBA, demineralized freeze-dried bone allograft; ePTFE, expanded Poly-Tetra-Fluor-Ethylene;
FDP, fixed dental prosthesis; FMPS, full-mouth plaque score; GBR, guided bone regeneration; KM, keratinized mucosa; N, none; NR, T A B L E 2 (Continued) [In PDF format, this table is best viewed in two-page mode]
[IQR]: 0), 2.6 ± 1.6 for "comparability" (median: 1, IQR: 0) and 3.8 ± 2.8
for "exposure/outcome" (median: 3, IQR: 0.5) ( Table 3) .
One randomized clinical trial (Zuffetti et al., 2016) statement. Two points were given to "selection of bias," one to "detection of bias" and one to "reporting bias" (Table 4) .
| DISCUSSION
The aim of the present systematic review was to investigate and compare the prevalence of biological complications and failure of implants placed in pristine sites vs. augmented sites after a mean observation period of at least 10 years. The outcomes of the metaanalysis failed to reveal any statistically significant differences 
between implants placed in pristine and augmented sites for any outcome variables both at patient and implant levels, respectively. This limitation was overcome in a randomized controlled trial by selecting implants of different length in cases of vertical bone augmentation in the anterior mandible followed by prosthetic rehabilitation with an overdenture (Visser et al., 2016) . The results of that RCT, however, indicated that implants with a length of 13-18 mm placed in mandibular sites augmented with anterior iliac crest yielded a significantly lower survival rate (88.7%) compared with that of implants with a length of 8-11 mm placed in pristine bone (98.7%) up to 15 years (Visser et al., 2016) . Hence, these outcomes (Visser et al., 2016) are in partial agreement with the findings of the present systematic review as even though the meta-analysis failed to show statistical significance, failure rate was higher for implants placed in augmented sites compared with pristine sites.
It was observed that only three of eight studies included in the present systematic review reported data on the history of treated periodontitis prior to implant placement (Roccuzzo, Bonino, et al., 2014; Roccuzzo et al. 2017; Simion et al., 2016) . This might stand for one of the reasons of the high variability of the outcomes in the present systematic review as history of periodontal disease is regarded as the major risk factor for peri-implantitis (Derks et al., 2016; Sanz & Chapple, 2012) . Findings from several studies indicated that patients treated for chronic or aggressive periodontitis may experience more biological complications and implant failures compared with non-periodontitis patients (AguirreZorzano et al., 2015; Derks et al., 2016; Monje et al., 2014; Sgolastra, Petrucci, Severino, Gatto, & Monaco, 2015; Sousa et al., 2016) . In fact, outcomes of a recent publication on the effectiveness of implant therapy in a Swedish population sample indicated that significantly higher odds ratios (ORs) for moderate/severe peri-implantitis were found for patients diagnosed with periodontitis (OR 4.08) compared with periodontally healthy patients (Derks et al., 2016) .
Moreover, the endpoints of periodontal therapy were shown to impact on the survival and success rates of dental implants (Pjetursson et al., 2012) . The presence of residual pocket probing depths ≥5 mm and bleeding on probing scores ≥ 30% at the end of active periodontal therapy represented a significant risk of peri-implantitis and implant loss over a mean follow-up period of 7.9 years (Pjetursson et al., 2012) . In addition, patients adhering to regular supportive periodontal therapy (SPT) and developing periodontal re-infections were at greater risk of peri-implantitis and implant failure compared with periodontally stable patients Pjetursson et al., 2012) .
All studies included in the present systematic review reported on the enrolment of patients in SPT following implant therapy. In this respect, it is well established that patients not enrolled in regular SPT suffer from higher prevalence of peri-implantitis and implant failure compared with patients enrolled in SPT Roccuzzo, Bonino, et al., 2014; Rokn et al., 2017; Salvi & Zitzmann, 2014) .
F I G U R E 3 Forest plot of the weighted mean prevalence of peri-implantitis at patient level of implants placed in pristine vs. augmented sites F I G U R E 6 Forest plot of the weighted mean prevalence of peri-implantitis at implant level of implants placed in pristine vs. augmented sites F I G U R E 5 Forest plot of the weighted mean prevalence of peri-implant mucositis at implant level of implants placed in pristine vs. augmented sites F I G U R E 4 Forest plot of the weighted mean prevalence of failure at patient level of implants placed in pristine vs. augmented sites Different augmentation techniques (e.g., alveolar ridge preservation or vertical ridge augmentation), different materials (e.g., autogenous bone or bone substitutes) and different barrier membranes (e.g., resorbable and non-resorbable) were used in the four studies reporting on implant placement in augmented sites (Daubert et al., 2015; Roccuzzo, Gaudioso, et al., 2014; Roccuzzo et al. 2017; Simion et al., 2016) . Hence, the variety of materials and protocols used for bone augmentation could not be assessed in the meta-analysis but it may be assumed that it plays a role on the long-term prevalence of biological complications and implant failure reported in the present systematic review. Findings from a recent systematic review yielded a comparable risk for wound healing complications when using resorbable (18.3%) vs.
non-resorbable membranes (17.6%) (Lim, Lin, Monje, Chan, & Wang, 2017) . Nevertheless, it is known that non-exposed sites achieve a sixfold greater bone gain compared with augmented sites where wound dehiscence occurred (Machtei, 2001) . Hence, findings from the present systematic review should be interpreted with caution due to the impossibility to perform subset analysis to gain insight on the impact of the augmentation procedure and/or biomaterials on the prevalence of peri-implant diseases.
| LIMITATIONS
Despite a comprehensive and strict screening process, some limitations might bias the outcomes of the present systematic review. Firstly, to the best of the authors' knowledge, no randomized controlled trials complying with ethical principles in cases where augmentation procedures were considered mandatory could be identified. Secondly, the included studies did not directly address the focused questions 
| FUTURE DIRECTIONS
The conduction of case-control studies in which patients with implants placed in augmented sites are matched with patients receiving implants in pristine sites and are prospectively evaluated should be encouraged. A higher level of evidence should include the performance of prospective cohort multi-centre studies in which patients in need of implants with augmentation procedures are recruited, treated according to standardized protocols and a priori-determined materials and enrolled in regular long-term maintenance to better capture the onset of disease.
| CONCLUSIONS
The studies included in the present systematic review did not directly address the focused questions. Hence, the outcomes of the metaanalysis should be interpreted with caution due to high variability with respect to patient sampling, case definitions of biological complications and eligibility criteria. Nevertheless, within the limitations of the present systematic review, patients receiving implants in augmented sites displayed higher variability and lower predictability in terms of peri-implantitis compared with patients receiving implants in pristine sites. Accordingly, future clinical trials should investigate the impact of augmentation procedures on implant outcomes controlling for other potential confounders and standardizing the alveolar bony defects.
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